SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
IDXG

Interpace Biosciences, Inc. (OTC:IDXG)

US · Delayed Price · Currency is USD
Healthcare · Medical - Diagnostics & Research
$4.40-$1.03 (-19.04%)
 
Market cap
$26.0M
Insider Score
Health Score
Analyst consensus
Listed since
May 20, 1998
Market Cap$25.97M+6.0%
Revenue (ttm)$37.76M-9.7%
Net Income$21.93M+355.8%
EPS$3.98+498.7%
Shares Out5.90M
PE Ratio0.17
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,800
Open$4.60
Previous Close$5.43
Day's Range$4.40 - $4.60
52-Week Range$0.83 - $12.00
Beta0.64
AnalystsBuy
Price Targetn/a
Earnings DateMar 31, 2027
-19.04% (1D)
No price history available.

About IDXG

Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic test for pancreatic cysts and solid lesions within the pancreaticobiliary system. This test, powered by the proprietary PathFinderTG platform, assists medical professionals in more accurately determining the risk of pancreaticobiliary cancers. It also offers PanDNA, a molecular-only variant of PancraGEN, which delivers insights into a select number of diagnostic markers. For thyroid health, the company provides ThyGeNEXT, an oncogenic mutation panel designed to identify malignant thyroid nodules. Additionally, ThyraMIR evaluates thyroid nodules for malignancy risk through the application of its proprietary microRNA gene-expression assay. Furthermore, RespriDx is a genomic diagnostic tool that aids clinicians in distinguishing between metastatic and recurrent lung cancer. Interpace Biosciences further supports the pharmaceutical and biotechnology sectors with services including pharmacogenomics testing, genotyping, biorepository solutions, and various custom scientific offerings. Its clientele primarily consists of physicians, hospitals, and clinics. Previously operating as Interpace Diagnostics Group, Inc., the company adopted its current name, Interpace Biosciences, Inc., in November 2019. Founded in 1986, its corporate headquarters are located in Parsippany, New Jersey.

Address
Waterview Plaza, Parsippany, NJ, 07054, US
Market Cap
26 million
Employees
102
Industrial Classification
Medical - Diagnostics & Research
Financial Health Score
Sound
From IDXG’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-19.04%
5 Days
-27.63%
1 Month
-18.52%
6 Months
-51.65%
1 Year
+6.02%

$IDXG stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in IDXG holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by IDXG's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

IDXG Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New IDXG patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to IDXG from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from IDXG’s recent data — informational, not investment advice

Generating analysis…

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.